Quick Answer
Foghorn Therapeutics Inc. reported Research And Development Expense of $85.47 million for the year ending 2025.
- Foghorn Therapeutics Inc. showed a decrease of -9.6% in Research And Development Expense from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $11.29 million | Q1 2020: $11.50 million | Q2 2020: $13.63 million | Q3 2020: $16.11 million | Q1 2021: $18.73 million | Q2 2021: $18.64 million | Q3 2021: $20.49 million | Q1 2022: $24.51 million | Q2 2022: $25.97 million | Q3 2022: $26.93 million | Q1 2023: $29.99 million | Q2 2023: $29.25 million | Q3 2023: $26.25 million | Q1 2024: $25.53 million | Q2 2024: $23.80 million | Q3 2024: $24.69 million | Q1 2025: $21.63 million | Q2 2025: $21.79 million | Q3 2025: $20.00 million.
- Over the full 7 years of available data (2019 to 2025), Foghorn Therapeutics Inc.'s Research And Development Expense has grown by 92.7%.
- Historical annual values: Fiscal year 2025: $85.47 million | Fiscal year 2024: $94.53 million | Fiscal year 2023: $109.69 million | Fiscal year 2022: $105.62 million | Fiscal year 2021: $80.33 million | Fiscal year 2020: $57.72 million | Fiscal year 2019: $44.36 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: